Suppl Table 2 and Figure 2 from <i>LRP1b</i> Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial
Publication
, Other
Armstrong, AJ; Dietz, H; Balli, D; Geese, WJ; Duan, C; Hung, Y-H; Ip, V; Li, G; Graf, RP; Ready, N
December 15, 2025
Duke Scholars
Citation
APA
Chicago
ICMJE
MLA
NLM
Armstrong, A. J., Dietz, H., Balli, D., Geese, W. J., Duan, C., Hung, Y.-H., … Ready, N. (2025). Suppl Table 2 and Figure 2 from <i>LRP1b</i> Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial. https://doi.org/10.1158/1078-0432.30883078
Armstrong, Andrew J., Hilary Dietz, David Balli, William J. Geese, Chunzhe Duan, Yu-Han Hung, Virginia Ip, Gerald Li, Ryon P. Graf, and Neal Ready. “Suppl Table 2 and Figure 2 from <i>LRP1b</i> Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial,” December 15, 2025. https://doi.org/10.1158/1078-0432.30883078.
Armstrong AJ, Dietz H, Balli D, Geese WJ, Duan C, Hung Y-H, et al. Suppl Table 2 and Figure 2 from <i>LRP1b</i> Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial. 2025.
Armstrong, Andrew J., et al. Suppl Table 2 and Figure 2 from <i>LRP1b</i> Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial. 15 Dec. 2025. Crossref, doi:10.1158/1078-0432.30883078.
Armstrong AJ, Dietz H, Balli D, Geese WJ, Duan C, Hung Y-H, Ip V, Li G, Graf RP, Ready N. Suppl Table 2 and Figure 2 from <i>LRP1b</i> Loss Predicts Sensitivity to Immunotherapy in Patients with NSCLC: An Analysis of the Phase III CheckMate-026 Randomized Trial. 2025.